Form 8-K - Current report:
SEC Accession No. 0001193125-22-173902
Filing Date
2022-06-14
Accepted
2022-06-14 16:58:06
Documents
13
Period of Report
2022-06-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d364118d8k.htm   iXBRL 8-K 41341
2 EX-10.1 d364118dex101.htm EX-10.1 49321
  Complete submission text file 0001193125-22-173902.txt   235574

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA inkt-20220608.xsd EX-101.SCH 2873
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE inkt-20220608_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inkt-20220608_pre.xml EX-101.PRE 11719
7 EXTRACTED XBRL INSTANCE DOCUMENT d364118d8k_htm.xml XML 3507
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40908 | Film No.: 221015549
SIC: 2836 Biological Products, (No Diagnostic Substances)